Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 12
Submit an article Journal homepage
449
Views
98
CrossRef citations to date
0
Altmetric
Drug Evaluation

Review of the proliferation inhibitor everolimus

Björn Nashan Klinik für Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, Germany
Pages 1845-1857 | Published online: 24 Feb 2005

Bibliography

  • HUSSAR DA: New drugs of 1999.j Am. Pharmacem. Soc. (2000) 40:181–221.
  • SEDRANI R, COTTENS S, KALLEN J, SCHULER W: Chemical modification of rapamycin: the discovery of SDZ PAD. Transplant. Proc. (1998) 30:2192–2194.
  • HUMAR A, PAYNE WD, SUTHERLAND DE, MATAS AJ: Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation (2000) 69:2357–2360.
  • PAUL LC: Chronic allograft nephropathy: an update. Kidney Int. (1999) 56:783–793.
  • MONACO AP, BURKE JF Jr, FERGUSON RIVI et al.: Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion. Am. J. Kidney Dis. (1999) 33(1):150–160.
  • MEIER-KRIESCHE HU, OJO AO, HANSON JA et al.: Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation (2000) 70:1098–1100.
  • HUMAR A, KERR S, GILLINGHAM KJ, MATAS AJ: Features of acute rejection that increase risk for chronic rejection. Transplantation (1999) 68:1200–1203.
  • TEJANI A, SULLIVAN EK: The impact of acute rejection on chronic rejection: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr. Transplant. (2000) 4:107–111.
  • •Analysis of a database of 6000 paediatric patients showing the pivotal impact of acute rejection on chronic rejection.
  • MATAS AJ, HUMAR A, PAYNE WD et al.: Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann. Surg. (1999) 230:493–500.
  • HUMAR A, GILLINGHAM KJ, PAYNE WD, DUNN DL, SUTHERLAND DER, MATAS AJ: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation (1999) 68:1879–1883.
  • FRENCH CG, BELITSKY P, LAWEN JG: Progress in renal transplantation. Can. J. Urol. (2000) 7:1030–1037.
  • DE MATTOS AM, OLYAEI AJ, BENNETT WM: Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am. J. Kidney Dis. (2000) 35:333–346.
  • BELITSKY P: Neoral use in the renal transplant recipient. Transplant. Proc. (2000) 32 (Suppl. 3A) : 1 0S–195.
  • SCHULER W, SEDRANI R, COTTENS S et al.: SDZ PAD, a new rapamycin derivative. Pharmacological properties in vitro and in vivo. Transplantation (1997) 64:36–42.
  • BOHLER T, WAISER J, BUDDE K et al: The in vivo effect of rapamycin derivative SDZ PAD on lymphocyte proliferation. Transplant. Proc. (1998) 30:2195–2197.
  • SCHUURMAN HJ, COTTENS S, FUCHS S et al: SDZ PAD, a new rapamycin derivative. Transplantation (1997) 64:32–35.
  • KELLY P, GRUBER SA, BEHBOD F, KAHAN BD: Sirolimus, a new potent immunosuppressive agent. Pharmacotherapy (1997) 17:1148–1156.
  • VILELLA-BACH M, NUZZI P, FANG Y, CHEN J: The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and progression. Biol. Chem. (1999) 274:4266–4272.
  • SCHUURMAN HJ, RINGERS J, SCHULER W, SLINGERLAND W, JONKER M: Oral efficacy of the macrolide immunosuppressant SDZ PAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation (2000) 69:737–742.
  • SCHUURMAN HJ, SCHULER W, RINGERS J, JONKER M: The macrolide SDZ PAD is efficacious in a nonhuman primate model of allotransplantation. Transplant. Proc. (1998) 30:2198–2199.
  • YAMASHITA K, HASHIMOTO T, KOBAYASHI T, NAN H, FURUKAWA H, TODO S: Effect of new immunosuppressants PAD and FTY720 on rat liver transplantation. 2001: A Transplant Odyssey The Future B Here. Istanbul, Turkey (2001):FC3.8.
  • HAUSEN B, BOEKE K, BERRY GJ, SEGARRA IT, CHRISTIANS U, MORRIS RE: Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ PAD) used alone and in combination with a microemulsion formulation of cyclosporine. I Heart Lung Transplant. (1999) 18:150–159.
  • HAUSEN B, BOEKE K, BERRY GJ et al.:Coadministration of Neoral and the novel rapamycin analog, SDZ PAD, to rat lung allograft recipients. Transplantation (1999) 67:956–962.
  • HAUSEN B, BOEKE K, BERRY GJ, CHRISTIANS U, SCHULER W, MORRIS RE: Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-PAD. Ann. Thome. Sing. (2000) 69:904–909.
  • HAUSEN B, IKONEN T, BRIFFA N et al.: Combined immunosuppression with cyclosporine (Neoral) and SDZ PAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation (2000) 69:76–86.
  • SERKOVA N, HAUSEN B, BERRY GJ et al.: Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-PAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. Pharmacol. Exp. Ther. (2000) 294:323–332.
  • HAUSEN B, GUMMERT J, BERRY GJ et al.: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients. Transplantation (2000) 69:488–496.
  • VIKLICKY 0, ZOU H, MOLLER V, LACHA J, SZABO A, HEEMANN U: SDZ-PAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation (2000) 69:497–502.
  • COLE 0J, SHEHATA M, RIGG KM: Effect of SDZ PAD on transplant arteriosclerosis in the rat aortic model. Transplant. Proc. (1998) 30:2200–2003.
  • SCHUURMAN HJ, PALLY C, WECKBECKER G, SCHULER W, BRUNS C: SDZ PAD inhibits cold ischemia-induced vascular remodeling. Transplant. Proc. (1999) 31:1024–1025.
  • SALMINEN US, MAASILTA PK, TASKINEN El, ALHO HS, IKONENE TS, HARJULA AU: Prevention of small airway obliteration in a swine heterotropic lung allograft model. Heart Lung Transplant. (2000) 19:193–206.
  • MAJEWSKI M, KORECKA M, KOSSEV P et al.: The immunosuppressive macrolide PAD inhibits growth of the human Epstein-Barr virus-transformed B lymphocytes M vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Nati Acad. Sci. USA (2000) 97:4285–4290.
  • SERKOVA N, LITT L, LEIBFRITZ D et al.: The novel immunosuppressant SDZ-PAD protects brain slices from cyclosporine-induced reduction of high-energy phosphates. Br. .1 Pharmacol. (2000) 129:485–492.
  • QUESNIAUX VFJ, MENNINGER K, KUNKLER A et al.: The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgous monkeys when given alone, with cyclosporine Neoral ° or with PAD. Transplant Immunol. (2000) 8:177–187.
  • NIKLOVA Z, HOF A, BAUMLIN Y, HOFRP: The peripheral lymphocyte count predicts graft survival in DA to Lewis heart transplantation treated with FTY720 and SDZ PAD. Transplant Immunol. (2000) 8:115–124.
  • BRINKMANN V, ALBERT R, WILT C, KRISTOFIC C, FENG S, HOF R: FTY720, a novel transplantation drug that modulates lymphocyte migratory responses: potential role of lysophospholipid receptors. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):512.1.
  • KIRCHNER GI, WINKLER M, MUELLER L et al.: Pharmacokinetics of SDZ PAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ PAD. Br. Clin. Pharmacol. (2000) 50:449–454.
  • KAHAN BD, WONG RL, CARTER C et al.: A Phase I study of a 4-week course of SDZ-PAD (PAD) in quiescent cyclosporine-treated renal transplant recipients. Transplantation (1999) 68:1100–1106.
  • NEUMAYER HH, PARADIS K, KORN A et al.: Entry-into-human study with the novel immunosuppressant SDZ PAD in stable renal transplant recipients. Br. Clin. Pharmacol. (1999) 48:694–703.
  • KOVARIK JM, KAHAN BD, KAPLAN B et al.: Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin. Pharmacol. The]: (2001) 69:48–56.
  • KOVARIK JM, HSU CH, MCMAHON L, BERTHIER S, RORDORF C: Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Pharmacol. The]: (2001) 70:247–254.
  • KOVARIK JM, SABIA H, ROUILLY M et al.: Influence of renal and hepatic impairment on everolimus pharmacokinetics: Are dose adjustments necessary? Am. .1 Transplant. (2001) l\(Suppl. 1):989.
  • LEVY GA, GRANT D, PARADIS K, CAMPESTRINI J, SMITH T, KOVARIK JM: Pharmacokinetics and tolerability of 40-0- [2-hydroxyethyl]rapamycin in de novo liver transplant recipients. Transplantation (2001) 71:160–163.
  • LEVY G: A one-year, multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability, and pharmacokinetics of PAD in de novo liver transplant recipients. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):S8.2.
  • KIRCHNER GI, VIDAL C, WINKLER M et al.: LC/ESI-MS allows simultaneous and specific quantification of SDZ PAD and cyclosporine, including groups of their metabolites, in human blood. Titer. Drug Monitor. (1999) 21:116–122.
  • VIDAL C, KIRCHNER GI, WUNSCH G, SEWING KF: Automated simultaneous quantification of the immunosuppressants 40-0- (2-hydroxyethy9 rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection. Clin. Chem. (1998) 44:1275–1282.
  • VIDAL C, KIRCHNER GI, SEWING KF: Structural elucidation by electrospray mass spectrometry: An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ PAD. I Am. Soc. Mass Specmom. (1998) 9:1267–1274.
  • KOVARIK JM, KALBAG J, FIGUEIREDO J, ROUILLY M, O'BANNON LF, RORDORF C: Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. Clin. Pharmacol (2002) 42: 95–99.
  • KOVARIK JM, HARTMANN S, FIGUEIREDO J et al.: Rifampin (a P450 enzyme-inducer) significantly increases the clearance of everolimus: implications for coadministration. Am. Transplant. (2001) 1 (Suppl. 1):643.
  • KAHAN BD, KAPLAN B, LORBER MI, WINKLER M, CAMBON N, BOGER RS: PAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71:1400–1406.
  • VITKO -8, MARGREITER R, WEIMAR W et al.: Everolimus (Certicanl 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (In press).
  • TEDESCO-SILVA H, KAPLAN B, MENDEZ R et al: Certican-" (PAD, everolimus) is complementary with Neoral in preventing organ rejection as part of triple therapy in de novo renal transplant recipients. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):S18.5.
  • MOURAD G, NASHAN B, CURTIS J et al.: Certican (PAD; everolimus), the proliferation signal inhibitor, is complementary with a reduced dose Neoral based quadruple immunosuppressive regimen. 2001:A Transplant Odyssey The future is here. Istanbul, Turkey (2001):S18.1.
  • ETTENGER R: CerticanIM in combination with Neoral® in pediatric de novo renal transplant patients: interim analysis at 3 months demonstrated no occurrence of biopsy-proven acute rejection, graft loss or death. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):D6.2a.
  • KOVARIK JM, KAPLAN B, TADESCO SILVA H et al.: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 73:920–925.
  • CURTIS J, NASHAN B, KOVARIK JM et al.: PAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine. Am.' Transplant. (2001) 1 (Suppl. 1):651.
  • PONTICELLI C, GLOTZ D, ZIALTEL V et al.: CerticanTM with reduced dose Neoral results in a significantly higher GFR in de novo renal transplant recipients over the first 12 months compared to Certican-full dose Neoral as assessed by isohexol clearance. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):S18.2.
  • EISEN H, DORENT R, MANCINI D et al.: Safety and efficacy of everolimus (PAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis. Heart Lung Transplant. (2002) 21:55.
  • KAHAN B: FY720 in combination withPAD: a calcineurin antagonist-free maintenance immunosuppression strategy. 2001:A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):S12.5.
  • JOHNSON RW, KREIS H, OBERBAUER R, BRATTSTROM C, CLAESSON K, ERIS J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 72:777–786.
  • PRIMMETT DR, LEVINE M, KOVARIK JM, MUELLER EA, KEOWN PA: Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Thec Drug Monitor. (1998) 20:276–283.
  • CANTAROVICH M, BESNER JG, BARKUN JS, ELSTEIN E, LOERTSCHER R:Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Gin. Transplant. (1998) 12:243–249.
  • LEVY GA: C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. BioDrugs (2001) 15:279–290.
  • KAHAN B: Management of the maintenance renal transplant recipient using Neoral® C2 monitoring. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):PII.3.
  • LEVY G: Neoral® C2 in the de novo and maintenance liver transplant. 2001: A Transplant Odyssey The Future is Here. Istanbul, Turkey (2001):PII.4.

Patents

Websites

  • http://www.patients.unos.org/data.htm TRANSPLANT PATIENT DATASOURCE: Richmond, VA: United Network for Organ Sharing. February 16 2000 A useful resource for US transplantation data.
  • http://www.datastarweb.com SCRIP DAILY ONLINE: 13 Dec 1999, S00647362.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.